.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Updates from ASCO 2025 in Advanced Non‒Small Cell Lung Cancer

EP. 1: Updates from ASCO 2025 in Advanced Non‒Small Cell Lung Cancer

July 8th 2025

On June 1, 2025, OncLive® convened a group of early career medical oncologists specializing in thoracic malignancies to discuss pivotal abstracts from the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO 2025). The session was moderated by Eric K. Singhi, MD, with faculty providing real-world perspectives on emerging therapies, treatment sequencing challenges, and evolving biomarker strategies. The discussion centered on antibody-drug conjugates (ADCs), targeted therapies for oncogene-driven NSCLC, perioperative treatment approaches, and novel diagnostic tools.